The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 16, 2020
Filed:
Dec. 22, 2015
Applicant:
Checkmate Pharmaceuticals, Inc., Cambridge, MA (US);
Inventor:
Arthur M. Krieg, Cambridge, MA (US);
Assignee:
CHECKMATE PHARMACEUTICALS, INC., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/70 (2006.01); A61K 38/21 (2006.01); C12N 15/63 (2006.01); C12N 15/117 (2010.01); A61K 39/395 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 31/713 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/70 (2013.01); A61K 31/713 (2013.01); A61K 39/39541 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/10 (2013.01); C07K 16/2818 (2013.01); C12N 15/117 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C12N 2310/17 (2013.01); C12N 2320/31 (2013.01);
Abstract
Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.